Glenmark Speclt Company Profile

What is the competitive landscape for GLENMARK SPECLT

GLENMARK SPECLT has twenty-nine approved drugs.

There are sixteen US patents protecting GLENMARK SPECLT drugs.

There are ninety-five patent family members on GLENMARK SPECLT drugs in thirty-five countries and one hundred and five supplementary protection certificates in sixteen countries.

Summary for Glenmark Speclt

International Patents:	95
US Patents:	16
Tradenames:	24
Ingredients:	23
NDAs:	29

Drugs and US Patents for Glenmark Speclt

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Speclt	CALCIPOTRIENE	calcipotriene	CREAM;TOPICAL	205772-001	Jun 9, 2015	AB	RX	No	No
Glenmark Speclt	FLUTICASONE PROPIONATE	fluticasone propionate	SPRAY, METERED;NASAL	218742-001	Mar 16, 2026		OTC	No	No
Glenmark Speclt	APREPITANT	aprepitant	CAPSULE;ORAL	207777-001	Oct 12, 2017	AB	RX	No	No
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes	10,646,500
Glenmark Speclt	SOLIFENACIN SUCCINATE	solifenacin succinate	TABLET;ORAL	209239-002	May 20, 2019	AB	RX	No	No

International Patents for Glenmark Speclt Drugs

Country	Patent Number	Estimated Expiration
Australia	2018260934
Australia	2025203489
China	109475495
European Patent Office	3043773
World Intellectual Property Organization (WIPO)	2019162902

Supplementary Protection Certificates for Glenmark Speclt Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0734381	3/2004	Austria		PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
3043773	122021000085	Germany		PRODUCT NAME: MOMETASON ODER EIN SALZ DAVON UND OLOPATADIN ODER EIN SALZ DAVON; NAT. REGISTRATION NO/DATE: 2205824.00.00 20211117; FIRST REGISTRATION: OESTERREICH 140638 20210426
0748320	SPC/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Glenmark Generics
• Glenmark Pharms
• Glenmark Pharms Ltd
• Glenmark Speclt
• Glenwood

Glenmark Specialty (Glenmark Speclt): Competitive Landscape Analysis, Patent/Regulatory Position, and Generic/Biosimilar Risk

Last updated: June 17, 2026

Glenmark Specialty’s market position and near-term competitive exposure depend on the specific Glenmark “Speclt” portfolio assets tied to the relevant markets (US/Europe/India) and the relevant product-level patent estates. A patent and regulatory competitive landscape for “Glenmark Speclt” cannot be completed from the information provided because no specific drug(s), strength(s), dosage form(s), FDA NDA/BLA identifiers, Orange Book entries, or jurisdictional filings were supplied.

Key issue: which product(s)

• “Glenmark Speclt” can refer to different Glenmark specialty products across territories and time periods. Patent expiration timelines, Paragraph IV eligibility, exclusivity windows, and biosimilar/generic entry risks are product-specific and must be anchored to identifiable regulators listings and patent numbers.

Because no product identity was provided, the analysis below is omitted to avoid generating incomplete or inaccurate patent timelines and litigation/regulatory status.

Key Takeaways

• A complete competitive landscape for Glenmark Specialty requires product-level identification (active ingredient, dosage form, market, and regulator listing such as FDA NDA/BLA and Orange Book patents).
• Patent expiration, exclusivity, and generic entry risk are not computable at the portfolio label level.

FAQs

1. What portfolio-level factors determine generic and biosimilar entry risk for Glenmark Specialty?
2. How do Orange Book patent listings translate into Paragraph IV attack timing windows?
3. What litigation patterns most often affect US specialty product launch dates?
4. How do formulation and method-of-use patents change generic design-around strategies?
5. What commercial KPIs best predict which Glenmark Specialty products face near-term erosion?

References

(No sources cited because no product identifiers, regulator listings, or patent datasets were provided.)